Global heparin market is expected to reach USD 14.32 billion by end of 2023, growing at a CAGR of around 6.20% between 2017 and 2023.
The report covers forecast and analysis for the heparin market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2023 based revenue (USD Billion). The study includes drivers and restraints for the heparin market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the heparin market on a global level.
In order to give the users of this report a comprehensive view on the heparin market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product type segment, type of form segment and type of formulation segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.
The study provides a decisive view on the heparin market by segmenting the market based on product type, source type, type of formulation and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2023. Based on product type the market is segmented into unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. On the basis of source type, the market is segmented into bovine and porcine. Based on the type of formulation the market is segmented into oral and parental. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Rest of North America, U.K., Germany, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Argentina, Rest of Latin America, Saudi Arabia, UAE, Qatar, South Africa and Rest of Middle East and Africa. This segmentation includes demand for heparin market based on individual product type, source, and type of formulation in all the regions and countries.
The report also includes detailed profiles of end players such as Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International, Inc., Syntex S.A., and Others.
This report segments the global heparin market as follows:
Global Heparin Market: Product Type Segment Analysis
Global Heparin Market: Source Type Segment Analysis
Global Heparin Market: Formulation Type Segment Analysis
Global Heparin Market: Regional Segment Analysis
What Reports Provides
This report is based on in-depth qualitative and quantitative analyses of the global Heparin market. Zion Market Research has collected and analyzed key data belong to the global Heparin market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Heparin across the world has been calculated through primary and secondary research.
Zion Market Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Market Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Heparin industry. Primary research makes up the major source of data collection and validation.
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases, and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Heparin market.
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
Heparin is an injectable anticoagulant, which is a compound used to prevent blood clotting. Heparin is widely used clinically in practices like dialysis (370,000 patients/year), deep vein thrombosis (DVT) treatment, flushing IVs and central lines, and most cardiac surgeries. Cardiac surgery represents one of the largest groups with over half a million surgeries being performed annually. While heparin is a valuable drug, improper use can cause severe hemorrhaging (bleeding out). When this happens, the options are to wait for the heparin to wear-off or administer an antidote. After warfarin, heparin is mostly recommended for the treatment of coagulation disorders and during surgical procedures.
The heparin market is growing steadily due to increasing incidences of coagulation disorders, substantial growth in the number of the people suffering from diseases like venous thromboembolism and heart diseases. The FDA receives approximately 450,000 reports of adverse drug events per year. In a study analyzing 250,000 events occurring in 2005, 3.8% were related to heparin, and harm was caused in 275 cases. Between 2007 and 2008, heparin use caused 246 deaths, 149 of which were from an allergic reaction. In 36% of cases, the error is due to the wrong dose or quantity, where 18% of the time the error is due to an overdose of 100x or more. In addition, the considerable rise in the prevalence of the obesity is also expected to support the global growth of this market.
Based on product type the market is segmented into unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. On the basis of source type, the market is segmented into bovine and porcine. Based on the type of formulation the market is segmented into oral and parental.
North America held a dominant share of the global heparin market which is attributed due to the sophisticated healthcare infrastructure; increasing number of medical tourists and a large number of surgical procedures conducted in the country. Asia-Pacific is projected to grow at a significant CAGR. The probability of pulmonary embolism in India, according to the National Institute of Health Consensus, is close to a 20.0%, whereas the overall incidence of DVT after elective hip surgery is approximately a 45.0% to 70.0%.
Some of the key players in the heparin market are Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International, Inc., Syntex S.A., and Others. Heparin market is expected to experience adoption of synthetic heparin by leading players in the industry. With the adoption of synthetic heparin, the global market is anticipated to augment the opportunities for the leading market player in the industry over the forecast period.
Request the coronavirus impact analysis across industries and markets